There's a new battle brewing between Eli Lilly (LLY) and Novo Nordisk (NVO) — and it could add to the projected $200 billion market for weight-loss drugs. Both companies have made a name for themselves in developing injections that mimic the GLP-1 hormone to improve feelings of satiety and blood sugar markers. But pills could be a major inflection point…
Extract — continue reading at the source.
Similar stories
2 outlets
See how this story developed, hour by hour
Eli Lilly, Stock Of The Day, Is Erasing Novo's Early Lead In Weight-Loss Pills
investors.com
18.08.2026
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start
finance.yahoo.com
17.08.2026
Related stories
Denny’s Goes All-In on Catering as Part of Comeback Plan
WTS UK picks Sharmila Sanmugam as partner
Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.
Hochschild Mining H1 Earnings Call Highlights
Strattec Security Q4 Earnings Call Highlights
Li Auto Q2 Earnings Call Highlights